Greenwich LifeSciences (GLSI) Return on Capital Employed (2020 - 2025)
Greenwich LifeSciences (GLSI) posted Return on Capital Employed of 2336.63% for Q4 2025, up 303.13% on a QoQ basis from 1150.33% in Q3 2025, and up 333069.0% year-over-year from N/an in Q4 2024.
Greenwich LifeSciences (GLSI) Return on Capital Employed (2020 - 2025) Analysis & Trends
Greenwich LifeSciences' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 2336.63% for Q4 2025.
- Quarterly Return on Capital Employed rose 333069.0% year-over-year to 2336.63% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 2336.63% (up 333069.0% YoY) and the FY2025 annual result came in at 2823.0%, up 357061.0% from the prior year.
- Return on Capital Employed was 2336.63% for Q4 2025 at Greenwich LifeSciences, up from 1150.33% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 2336.63% in Q4 2025 and bottomed at 1578.37% in Q2 2025.
- A 5-year average of 172.45% and a median of 74.88% in 2023 frame the typical range for Return on Capital Employed.
- Peak annual rise in Return on Capital Employed reached 333069 bps in 2025, while the deepest fall reached 136831 bps in 2025.
- Greenwich LifeSciences' Return on Capital Employed stood at 16.61% in 2021, then tumbled by 239 bps to 56.23% in 2022, then tumbled by 113 bps to 119.93% in 2023, then tumbled by 729 bps to 994.06% in 2024, then jumped by 335 bps to 2336.63% in 2025.
- Business Quant data shows GLSI's Return on Capital Employed at 2336.63% in Q4 2025, 1150.33% in Q3 2025, and 1578.37% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - | 2,336.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,336.63% |
| Sep 30, 2025 | -1,150.33% |
| Jun 30, 2025 | -1,578.37% |
| Mar 31, 2025 | -926.63% |
| Dec 31, 2024 | -994.06% |
| Sep 30, 2024 | -189.36% |
| Jun 30, 2024 | -210.06% |
| Mar 31, 2024 | -164.15% |
| Dec 31, 2023 | -119.93% |
| Sep 30, 2023 | -96.24% |
| Jun 30, 2023 | -83.23% |
| Mar 31, 2023 | -66.54% |
| Dec 31, 2022 | -56.23% |
| Sep 30, 2022 | -46.48% |
| Jun 30, 2022 | -32.92% |
| Mar 31, 2022 | -25.75% |
| Dec 31, 2021 | -16.61% |
| Sep 30, 2021 | -11.66% |
| Jun 30, 2021 | -9.38% |
| Mar 31, 2021 | -7.69% |